Neural Stem Cell-Based Anticancer Gene Therapy: A First-in-Human Study in Recurrent High-Grade Glioma Patients.

Abstract

Purpose: Human neural stem cells (NSC) are inherently tumor tropic, making them attractive drug delivery vehicles. Toward this goal, we retrovirally transduced an immortalized, clonal NSC line to stably express cytosine deaminase (HB1.F3.CD.C21; CD-NSCs), which converts the prodrug 5-fluorocytosine (5-FC) to 5-fluorouracil (5-FU).Experimental Design: Recurrent high-grade glioma patients underwent intracranial administration of CD-NSCs during tumor resection or biopsy. Four days later, patients began taking oral 5-FC every 6 hours for 7 days. Study treatment was given only once. A standard 3 + 3 dose escalation schema was used to increase doses of CD-NSCs from 1 × 107 to 5 × 107 and 5-FC from 75 to 150 mg/kg/day. Intracerebral microdialysis was performed to measure brain levels of 5-FC and 5-FU. Serial blood samples were obtained to assess systemic drug concentrations as well as to perform immunologic correlative studies.Results: Fifteen patients underwent study treatment. We saw no dose-limiting toxicity (DLT) due to the CD-NSCs. There was 1 DLT (grade 3 transaminitis) possibly related to 5-FC. We did not see development of anti-CD-NSC antibodies and did not detect CD-NSCs or replication-competent retrovirus in the systemic circulation. Intracerebral microdialysis revealed that CD-NSCs produced 5-FU locally in the brain in a 5-FC dose-dependent manner. Autopsy data indicate that CD-NSCs migrated to distant tumor sites and were nontumorigenic.Conclusions: Collectively, our results from this first-in-human study demonstrate initial safety and proof of concept regarding the ability of NSCs to target brain tumors and locally produce chemotherapy. Clin Cancer Res; 23(12); 2951-60. ©2016 AACR.

• Authors: Jana Portnow, Timothy W Synold, Behnam Badie, Revathiswari Tirughana, Simon F Lacey, Massimo D'Apuzzo, Marianne Z Metz, Joseph Najbauer, Victoria Bedell, Tien Vo, Margarita Gutova, Paul Frankel, Mike Chen, Karen S Aboody
• Journal: Clinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 23 Issue 12 Pg. 2951-2960 (Jun 15 2017) ISSN: 1557-3265 [Electronic] United States
• PMID: 27979915 (Publication Type: Clinical Trial, Phase I, Journal Article)
• Copyright: ©2016 American Association for Cancer Research.

Chemical References

• Flucytosine
• Cytosine Deaminase
• Fluorouracil

Topics

• Adolescent
• Adult
• Cytosine Deaminase (administration & dosage, adverse effects, genetics)
• Female
• Flucytosine (administration & dosage)
• Fluorouracil (administration & dosage)
• Gene Transfer Techniques
• Genetic Therapy
• Genetic Vectors
• Glioma (drug therapy, genetics, pathology)
• Humans
• Male
• Middle Aged
• Neoplasm Grading
• Neural Stem Cells (transplantation)